BioInformant

Your Global Leader in Stem Cell Market Research

Home » Exosomes

EVerZom raises €1.1M to industrialize its exosome biomanufacturing platform

By Leave a Comment

EVerZom’s ambition is to transform regenerative medicine and the field of biotherapies thanks to these «super» biological nanoparticles, the exosomes.

Paris, November 30, 2020 — EVerZom, a biopharmaceutical company specialized in the bioproduction of exosomes, announced today that it has raised €1.1 million in funding from institutional and private investors to develop its exosome bioproduction platform. This funding will speed up the platform development and scale-up, with the objective to allow routine clinical grade production by 2022. [Read more…]

Organicell Announces Additional Site for Phase I/II Clinical Trial of Zofin™ for Treatment of COVID-19

By Leave a Comment

Miami, FL (November 18, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I/II clinical trial for the use of its Zofin™ therapeutic in treatment of COVID-19. [Read more…]

Organicell Provides Update on Its COVID-19 Clinical Trial Using Zofin™

By Leave a Comment

  • Anticipates Phase I/II trial completion by end of year

  • Anticipates Phase IIb trial to begin in Q1 2021

  • Seeks to retain a global contract research organization (“CRO”)

Miami, FL (November 12, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today provided an update on its Phase I/II clinical trial for treatment of COVID-19 using Organicell’s proprietary therapeutic, Zofin™, which is currently underway as well as an update on its expanded access protocol for outpatients with COVID-19. [Read more…]

Nano-race: Industrial Landscape of Exosome-Based Therapeutics and Diagnostics

By

Exosomes are nano-sized vesicles ranging from 30-200nm that are present in eukaryotic fluids and facilitate a diverse range of cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.

Because of their far ranging potential, exosomes can be commercialized as therapeutic agents, diagnostic tools, and cosmeceuticals. Today, a surging number of companies are developing exosome-based products and technologies.

Exosome Market Competitors

Currently, there are at least 45 market competitors which compose the exosome industry in therapeutics and diagnostics. Twenty six of them are companies specializing in exosomes and nineteen of them are established companies that have recently jumped into the exosome industry.
[Read more…]

Exosome Companies | Tiny Exosomes, Enormous Potential

By

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits.

Exosome Companies and Exosome Therapies

In this article:

  1. What are Exosomes?
  2. Where are Exosomes Found?
  3. Exosome Therapeutics in Regenerative Medicine
  4. Exosome Market Momentum
  5. Companies Commercializing Exosome Technologies

[Read more…]

BioInformant's World-Class Clients